β-Lactam/β-Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts

被引:290
作者
Rodriguez-Bano, Jesus [1 ,2 ]
Navarro, Maria Dolores [1 ]
Retamar, Pilar [1 ]
Picon, Encarnacion [1 ]
Pascual, Alvaro [1 ,3 ]
机构
[1] Hosp Univ Virgen Macarena, Secc Enfermedades Infecciosas, Unidad Clin Enfermedades Infecciosas & Microbiol, Avda Dr Fedriani 3, Seville 41009, Spain
[2] Univ Seville, Dept Med, Seville, Spain
[3] Univ Seville, Dept Microbiol, Seville, Spain
关键词
BLOOD-STREAM INFECTIONS; PIPERACILLIN-TAZOBACTAM; KLEBSIELLA-PNEUMONIAE; ANTIBIOTIC-THERAPY; RISK-FACTORS; ENTEROBACTERIACEAE; RESISTANCE; STRAIN; SUSCEPTIBILITY; EPIDEMIOLOGY;
D O I
10.1093/cid/cir790
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In a post hoc analysis of prospective cohorts, carbapenems were not superior to in vitro active beta-lactam/beta-lactam inhibitor combinations (amoxicillin-clavulanic acid or piperacillin-tazobactam) in treatment of bacteremia caused by extended-spectrum ss-lactamase-producing Escherichia coli, mostly from urinary or biliary infections.Background. Extended-spectrum ss-lactamase-producing Escherichia coli (ESBL-EC) is an important cause of invasive infections. Alternatives to carbapenems-considered the drugs of choice-are needed because of the emergence of carbapenemase-producing enterobacteria. The efficacy of ss-lactam/ss-lactam inhibitors (BLBLI) in such infections is controversial. Methods. The authors performed a post hoc analysis of patients with bloodstream infections due to ESBL-EC from 6 published prospective cohorts. Mortality and length of hospital stay in patients treated with an active BLBLI (amoxicillin-clavulanic acid [AMC] and piperacillin-tazobactam [PTZ]) or carbapenem were compared in 2 cohorts: the empirical therapy cohort (ETC) and the definitive therapy cohort (DTC). Confounding was controlled by multivariate analysis; for patients in the ETC, a propensity score for receiving carbapenem was also used. Results. The ETC included 103 patients (BLBLI, 72; carbapenem, 31), and the DTC included 174 (BLBLI, 54; carbapenem, 120). Mortality rates at day 30 for those treated with BLBLI versus carbapenems were 9.7% versus 19.4% for the ETC and 9.3% versus 16.7% for the DTC, respectively (P > .2, log-rank test). After adjustment for confounders, no association was found between either empirical therapy with BLBLI (adjusted hazard ratio [HR], 1.14; 95% confidence interval [CI], .29-4.40; P = .84) or definitive therapy (adjusted HR, 0.76; 95% CI, .28-2.07; P = .5) and increased mortality. Furthermore, BLBLI therapy, with respect to carbapenem, was not found to influence length of hospital stay. Conclusions. These results suggest that AMC and PTZ are suitable alternatives to carbapenems for treating patients with bloodstream infections due to ESBL-EC if active in vitro and would be particularly useful as definitive therapy.
引用
收藏
页码:167 / 174
页数:8
相关论文
共 42 条
[1]   Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases:: Report from the ARREST program [J].
Ambrose, PG ;
Bhavnani, SM ;
Jones, RN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1643-1646
[2]   Predictors of mortality from community-onset bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae [J].
Apisarnthanarak, Anucha ;
Kiratisin, Pattarachai ;
Mundy, Linda M. .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2008, 29 (07) :671-674
[3]  
Borer A, 2002, MED SCI MONITOR, V8, pCR44
[4]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[5]   Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae [J].
Chaubey V.P. ;
Pitout J.D.D. ;
Dalton B. ;
Ross T. ;
Church D.L. ;
Gregson D.B. ;
Laupland K.B. .
BMC Research Notes, 3 (1)
[6]   Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria [J].
Chen, Yen-Hsu ;
Hsueh, Po-Ren ;
Badal, Robert E. ;
Hawser, Stephen P. ;
Hoban, Daryl J. ;
Bouchillon, Samuel K. ;
Ni, Yuxing ;
Paterson, David L. .
JOURNAL OF INFECTION, 2011, 62 (04) :280-291
[7]  
*CLIN LAB STAND I, 2010, M100S20 CLIN LAB STA
[8]  
Clinical and Laboratory Standards Institute, 2010, M100S20U CLIN LAB ST
[9]   Dissemination of clonally related Escherichia coli strains expressing extended-spectrum β-lactamase CTX-M-15 [J].
Coque, Teresa M. ;
Novais, Angela ;
Carattoli, Alessandra ;
Poirel, Laurent ;
Pitout, Johann ;
Peixe, Luisa ;
Baquero, Fernando ;
Canton, Rafael ;
Nordmannj, Patrice .
EMERGING INFECTIOUS DISEASES, 2008, 14 (02) :195-200
[10]   Diversity of Escherichia coli Strains Producing Extended-Spectrum β-Lactamases in Spain: Second Nationwide Study [J].
Diaz, Miguel A. ;
Hernandez-Bello, Jose R. ;
Rodriguez-Bano, Jesus ;
Martinez-Martinez, Luis ;
Calvo, Jorge ;
Blanco, Jorge ;
Pascual, Alvaro .
JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (08) :2840-2845